Autosomal Dominant Polycystic Kidney Disease
Symptoms, Doctors, Treatments, Advances & More

Autosomal Dominant Polycystic Kidney Disease Overview

Save information for later
Sign Up

Learn About Autosomal Dominant Polycystic Kidney Disease

What is the definition of Autosomal Dominant Polycystic Kidney Disease?
Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder characterized by the growth of numerous cysts in the kidneys. ADPKD is a progressive disease and symptoms tend to get worse over time. The most common symptoms are kidney cysts, pain in the back and the sides and headaches. Other symptoms include liver and pancreatic cysts, urinary tract infections, abnormal heart valves, high blood pressure, kidney stones, and brain aneurysms. ADPKD is most often caused by changes in the PKD1 and PKD2 genes, and less often by changes in the GANAB and DNAJB11 genes. It is inherited in a dominant pattern. ADPKD is the most common inherited disorder of the kidneys.
What are the alternative names for Autosomal Dominant Polycystic Kidney Disease?
  • Autosomal dominant polycystic kidney disease
  • ADPKD
  • Polycystic kidney disease, adult type
Who are the top Autosomal Dominant Polycystic Kidney Disease Local Doctors?
Frederic F. Oskoui
Elite in Autosomal Dominant Polycystic Kidney Disease
Dr. Frederic F. Oskoui
Intensive Care Medicine
Elite in Autosomal Dominant Polycystic Kidney Disease
Dr. Frederic F. Oskoui
Intensive Care Medicine

Emory University Hospital Midtown

550 Peachtree Street Northeast, 
Atlanta, GA 
404-686-2410
Experience:
6+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Frederic Oskoui is an Intensive Care Medicine provider in Atlanta, Georgia. Dr. Oskoui has been practicing medicine for over 6 years and is rated as an Elite provider by MediFind in the treatment of Autosomal Dominant Polycystic Kidney Disease. His top areas of expertise are Autosomal Dominant Polycystic Kidney Disease, Polycystic Kidney Disease, Chronic Kidney Disease, and End-Stage Renal Disease (ESRD).

Alan S. Yu
Elite in Autosomal Dominant Polycystic Kidney Disease
Dr. Alan S. Yu
Nephrology
Elite in Autosomal Dominant Polycystic Kidney Disease
Dr. Alan S. Yu
Nephrology

Medical Pavilion

2000 Olathe Boulevard, 
Kansas City, KS 
913-588-1227
Experience:
37+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Alan Yu is a Nephrologist in Kansas City, Kansas. Dr. Yu has been practicing medicine for over 37 years and is rated as an Elite provider by MediFind in the treatment of Autosomal Dominant Polycystic Kidney Disease. His top areas of expertise are Polycystic Kidney Disease, Autosomal Dominant Polycystic Kidney Disease, Chronic Kidney Disease, and Kidney Stones. Dr. Yu is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Meyeon Park
Elite in Autosomal Dominant Polycystic Kidney Disease
Dr. Meyeon Park
Nephrology
Elite in Autosomal Dominant Polycystic Kidney Disease
Dr. Meyeon Park
Nephrology

Nephrology And Hypertension Faculty Practice

400 Parnassus Ave., B1 Plaza Level, 
San Francisco, CA 
415-353-2507
Languages Spoken:
English, French, Spanish
See accepted insurances
Accepting New Patients

Dr. Meyeon Park is a nephrologist who cares for patients affected in various ways by high blood pressure and kidney disease. She has a special focus on polycystic kidney disease (PKD) and directs UCSF's PKD center of excellence. Park's research explores how heart disease and kidney disease influence each other. She is particularly interested in learning how lifestyle changes can help individuals with PKD. Park earned her medical degree from the Perelman School of Medicine at the University of Pennsylvania. She then completed a residency in internal medicine at the Yale School of Medicine, followed by a fellowship in nephrology at UCSF. She also has a master of advanced study degree in clinical research from UCSF. Park is a member of the American Society of Nephrology. Dr. Park is rated as an Elite provider by MediFind in the treatment of Autosomal Dominant Polycystic Kidney Disease. Her top areas of expertise are Polycystic Kidney Disease, Autosomal Dominant Polycystic Kidney Disease, Pseudohypoaldosteronism Type 2, Liddle Syndrome, and Kidney Transplant.

View All Doctors
What are the latest Autosomal Dominant Polycystic Kidney Disease Clinical Trials?
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of ABBV-CLS-628 in Adult Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of ABBV-CLS-628 in Adult Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Enrollment Status: Recruiting
Publish Date: February 04, 2026
Intervention Type: Drug
Study Phase: Phase 2

Summary: Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common genetic cause of kidney disease that causes fluid-filled cysts to develop in the kidneys. The purpose of this study is to assess the safety and efficacy of ABBV-CLS-628 for the treatment of ADPKD in adult participants. ABBV-CLS-628 is an investigational drug being developed for the treatment of ADPKD. Participants are placed i...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 2a, Open-label, Single-arm Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VX-407 in Subjects With Autosomal Dominant Polycystic Kidney Disease Who Have a Subset of PKD1 Gene Variants
A Phase 2a, Open-label, Single-arm Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VX-407 in Subjects With Autosomal Dominant Polycystic Kidney Disease Who Have a Subset of PKD1 Gene Variants
Enrollment Status: Recruiting
Publish Date: February 03, 2026
Intervention Type: Drug
Study Phase: Phase 2

Summary: The purpose of the study is to evaluate the effect of VX-407 on height-adjusted total kidney volume (htTKV), safety, tolerability, and pharmacokinetics (PK) of VX-407.

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center